Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
Shanghai Zhongshan Hospital
17 participants
Jan 31, 2026
INTERVENTIONAL
Conditions
Summary
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
Eligibility
Inclusion Criteria7
- Age 18-80 years, regardless of gender.
- Clinically or pathologically confirmed HCC.
- CNLC stage IIb-IIIa, deemed unresectable after multidisciplinary evaluation.
- Having radiologically evaluable, untreated target lesions for ablation, with the largest diameter of the target tumor >5 cm.
- Patients who have not undergone systemic chemotherapy, targeted therapy, or immunotherapy for hepatocellular carcinoma, or those who have been evaluated as SD (stable disease) or PD (progressive disease) after treatment..
- ECOG PS 0-1 and an expected survival >3 months.
- Child-Pugh score ≤7.
Exclusion Criteria14
- Child-Pugh class C liver dysfunction.
- Tumor thrombus in the main portal vein or hepatic vein.
- Extensive metastatic disease with an expected survival <3 months.
- Severe dysfunction of major organs (liver, kidney, heart, lung, or brain).
- History of esophageal/gastric variceal bleeding within the past month.
- History of other malignancies.
- Last anti-tumor therapy (e.g., radiotherapy, systemic chemotherapy, or local treatment) within <1 month.
- Active infection; HBV co-infection (HBV DNA ≥2000 IU/mL or ≥10⁴ copies/mL unless reduced by one log after antiviral therapy); HCV co-infection requiring guideline-directed antiviral treatment; HIV infection; or biliary tract inflammation.
- History of organ transplantation or hepatic encephalopathy.
- Uncorrectable coagulation disorders.
- Refractory massive ascites, pleural effusion, or cachexia.
- Pregnancy, impaired consciousness, or inability to comply with treatment.
- High tumor burden (sum of the largest liver lesion diameter and number of liver lesions >12).
- Any other condition deemed unsuitable by investigators that may affect study participation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06794073